CoChat

Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations

Open access

The DOI matches its Crossref record; 129 of the 130 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Coronavirus Disease 19 (COVID-19), due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become an on-going global health emergency affecting over 94 million cases with more than 2 million deaths globally. Primarily identified as atypical pneumonia, it has developed into severe acute respiratory distress syndrome (ARDS), a multi-organ dysfunction with associated fatality. Ever since its emergence, COVID-19 with its plethora of clinical presentations has signalled its dynamic nature and versatility of the disease process. Being a disease with droplet transmission has now assumed the proportion of a suspected airborne nature which, once proved, poses a Herculean task to control. Because of the wide distribution of the human angiotensin-converting enzyme-2 (hACE2) receptors, known for its transmission, we envisage its multiorgan spread and extensive disease distribution. Thus, an extensive review of the extrapulmonary organotropism of SARS-CoV-2 with organ-specific pathophysiology and associated manifestations like dermatological complications, myocardial dysfunction, gastrointestinal symptoms, neurologic illnesses, hepatic and renal injury is needed urgently. The plausible mechanism of site-specific viral invasion is also discussed to give a comprehensive understanding of disease complexity, to help us to focus on research priorities and therapeutic strategies to counter the disease progression. A note on the latest advancements in vaccine research will enlighten the scientific world and equip it for better preparedness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm10030446

Cites

129 of 130 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanism of hepatic injury: in coronavirus disease 2019 (COVID-19) patients, hepatic injury attributed by (i) direct virus-induced cytopathic effect; (ii) virus-mediated infection-induced cytokine storm. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE2), expressed on hepatocytes and cholangiocytes in the bile duct cells causing ablation of tight junction protein claudin 1 and down-regulation of apical sodium-dependent bile acid transporter (ASBT) and cystic fibrosis transmembrane conductance regulator (CFTR), leading to the accumulation of bile acids and contributing towards liver injury. Inflammatory cytokines (interleukin-6, IL-10, and IL-2) secretion by lymphocytes and macrophages aggravate inflammatory responses causing hepatic injury. Black dotted square frame in the figures denotes the selected area for the magnified portion.
Figure 1 Mechanism of hepatic injury: in coronavirus disease 2019 (COVID-19) patients, hepatic injury attributed by (i) direct virus-induced cytopathic effect; (ii) virus-mediated infection-induced cytokine storm. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE2), expressed on hepatocytes and cholangiocytes in the bile duct cells causing ablation of tight junction protein claudin 1 and down-regulation of apical sodium-dependent bile acid transporter (ASBT) and cystic fibrosis transmembrane conductance regulator (CFTR), leading to the accumulation of bile acids and contributing towards liver injury. Inflammatory cytokines (interleukin-6, IL-10, and IL-2) secretion by lymphocytes and macrophages aggravate inflammatory responses causing hepatic injury. Black dotted square frame in the figures denotes the selected area for the magnified portion.CC BY · PubMed Central
Figure 2 Mechanism of cardiac injury: In COVID-19 patients, SARS-CoV-2 mediated injury to cardiomyocyte, pericytes, and, capillary endothelial cells by expressing ACE2 receptor and elevating the heart susceptibility to SARS-CoV-2 infection, which induce microvascular myocardial microcirculation disorder and other cardiac abnormalities.
Figure 2 Mechanism of cardiac injury: In COVID-19 patients, SARS-CoV-2 mediated injury to cardiomyocyte, pericytes, and, capillary endothelial cells by expressing ACE2 receptor and elevating the heart susceptibility to SARS-CoV-2 infection, which induce microvascular myocardial microcirculation disorder and other cardiac abnormalities.CC BY · PubMed Central
Figure 3 Predictable model for SARS-CoV-2 induced neurological manifestations: Numerous pathways predicted for central nervous system CNS invasion by SARS-CoV-2 to cause neuronal damage. In the olfactory neuron transport, SARS-CoV-2 can infiltrate the CNS/brain through the olfactory tract by olfactory nerves in the nasal cavity/epithelium and the olfactory bulb in the forebrain, causing inflammation and demyelinating reactions. In the hematogenous route, SARS-CoV-2 binds to the receptor ACE2 expressed in the capillary endothelium and enters the CNS by a breach in the blood–brain barrier (BBB) resulting in high blood pressure with the risk of a cerebral hemorrhage. Infected and activated macrophages, microglia, astrocytes, and glial cells in the CNS induce a pro-inflammatory state by secretion of IL-6, IL-12, and IL-15 resulting in acute necrotizing encephalopathy (ANE), hyper inflammation, and encephalopathy.
Figure 3 Predictable model for SARS-CoV-2 induced neurological manifestations: Numerous pathways predicted for central nervous system CNS invasion by SARS-CoV-2 to cause neuronal damage. In the olfactory neuron transport, SARS-CoV-2 can infiltrate the CNS/brain through the olfactory tract by olfactory nerves in the nasal cavity/epithelium and the olfactory bulb in the forebrain, causing inflammation and demyelinating reactions. In the hematogenous route, SARS-CoV-2 binds to the receptor ACE2 expressed in the capillary endothelium and enters the CNS by a breach in the blood–brain barrier (BBB) resulting in high blood pressure with the risk of a cerebral hemorrhage. Infected and activated macrophages, microglia, astrocytes, and glial cells in the CNS induce a pro-inflammatory state by secretion of IL-6, IL-12, and IL-15 resulting in acute necrotizing encephalopathy (ANE), hyper inflammation, and encephalopathy.CC BY · PubMed Central
Figure 4 A predictive model for gastrointestinal (GIT) manifestations: High ACE2 expression and stronger binding efficiency of SARS-CoV-2 for ACE2 in absorptive intestinal epithelial cells (IECs), enterocytes in the ileum and colon, indirectly regulate intestinal inflammation and oesophageal erosion suggested the viral invasion to enterocytes of the digestive tract and stratified epithelial cells of the esophagus. High-expression of ACE2 receptors in the glandular cells of the gastric and duodenal epithelium, or proximal and distal enterocytes, leads to unbalanced intestinal secretion and mal-absorption resulting in diarrhea as a common GIT manifestation. Red dotted square frame in the figures denotes the selected area for the magnified portion.
Figure 4 A predictive model for gastrointestinal (GIT) manifestations: High ACE2 expression and stronger binding efficiency of SARS-CoV-2 for ACE2 in absorptive intestinal epithelial cells (IECs), enterocytes in the ileum and colon, indirectly regulate intestinal inflammation and oesophageal erosion suggested the viral invasion to enterocytes of the digestive tract and stratified epithelial cells of the esophagus. High-expression of ACE2 receptors in the glandular cells of the gastric and duodenal epithelium, or proximal and distal enterocytes, leads to unbalanced intestinal secretion and mal-absorption resulting in diarrhea as a common GIT manifestation. Red dotted square frame in the figures denotes the selected area for the magnified portion.CC BY · PubMed Central
Figure 5 Landscape representation of COVID-19 vaccine candidates in phase III clinical trials: BNT162b2 and mRNA 1273 vaccines are in the forefront and have been granted the Emergency Use Authorization (EUA) status. Adeno based vaccine by AstraZeneca is also the promising vaccines that may be soon approved for emergency use. Other COVID-19 vaccine players are Sinovac Biotech. Ltd (Beijing, China), CasSin Biologics Inc. (Tianjin, China), Novavax (Maryland, US), Inovio (San Diego, CA, US), Clover Biopharmaceuticals (Zhejiang, China), and GenNBio Inc. (Daegu, South Korea).
Figure 5 Landscape representation of COVID-19 vaccine candidates in phase III clinical trials: BNT162b2 and mRNA 1273 vaccines are in the forefront and have been granted the Emergency Use Authorization (EUA) status. Adeno based vaccine by AstraZeneca is also the promising vaccines that may be soon approved for emergency use. Other COVID-19 vaccine players are Sinovac Biotech. Ltd (Beijing, China), CasSin Biologics Inc. (Tianjin, China), Novavax (Maryland, US), Inovio (San Diego, CA, US), Clover Biopharmaceuticals (Zhejiang, China), and GenNBio Inc. (Daegu, South Korea).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 130 references

Cited by

See all 147

Metadata

Authors
Thakur, V., Ratho, R. K., Kumar, P., Bhatia, S. K., Bora, I., Mohi, G. K., Saxena, S. K., Devi, M., Yadav, D., & Mehariya, S.
Affiliations
  • Post Graduate Institute of Medical Education and Research (IN)
  • Shoolini University (IN)
  • Konkuk University (KR)
  • King George's Medical University (IN)
  • Rajasthan University of Health Sciences (IN)
  • Yeungnam University (KR)
  • University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
  • Ratho, Radha Kanta
  • Yadav, Dhananjay
  • Mehariya, Sanjeet
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2021-01-24
Volume
10
Issue
3
Pages
446
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3123500641
Cited by
147
References
124
Citations by year
2026: 5 · 2025: 18 · 2024: 15 · 2023: 33 · 2022: 45 · 2021: 31
FWCI
3.63
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Postgraduate Institute of Medical Education and Research, Chandigarh
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
COVID-19 pandemic, SARS-CoV-2, multi-organ involvement, extrapulmonary manifestations, severe acute respiratory distress syndrome, multiple organ failure, angiotensin-converting enzyme 2 receptor, viral tropism, skin complications, cardiac dysfunction, gastrointestinal symptoms, neurological complications, liver injury, kidney injury, COVID-19 vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.